



The Effect of Platelet Rich Plasma on the Treatment Outcome of Minigraft/NB-UVB Therapy in Stable Vitiligo: Clinical Evaluation and Effect on Tissue levels of bFGF

Thesis

*Submitted for Fulfillment of Master's Degree in
Dermatology, Venereology & Andrology*

By

Tabarek Abdulkhaleq Fezea

M.B, B. CH., Faculty of Medicine, Baghdad University

Under Supervision of

Prof. Dr. Samar Abdallah Mohamed Salem

*Professor of Dermatology, Venereology and Andrology
Faculty of Medicine, Ain-Shams University*

Dr. Marwa Yassin Soltan

*Lecturer of Dermatology, Venereology and Andrology
Department: Faculty of Medicine, Ain-Shams University*

Dr. Nashwa El Khazragy

*Lecturer of Clinical Pathology and Hematology
Faculty of Medicine, Ain-Shams University*

Faculty of Medicine
Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Samar Abdallah Mohamed Salem**, Professor of Dermatology, Venereology and Andrology, Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Marwa Yassin Soltan**, Lecturer of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Mashwa El Khazragy**, Lecturer of Clinical Pathology and Hematology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

Tabarek Abdulkhaleq

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations.....	vi
1. Introduction.....	1
2. Aim of the Study	6
3. Review of Literature	
3.1. Vitiligo.....	7
3.2. Vitiligo Treatment	34
4. Patients and Methods	67
5. Results	86
6. Discussion.....	115
7. Conclusion	126
8. Recommendations	127
9. Summary	128
References	131
Master Sheet	165
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Differential diagnoses for vitiligo.....	24
Table (2):	Assessment methods for the evaluation of vitiligo.....	27
Table (3):	Various surgical procedures	44
Table (4):	Medical management of vitiligo	65
Table (5):	Description of personal, medical and family history among study cases.....	87
Table (6):	Description of disease characteristics among study cases	89
Table (7):	Comparison between the two treatments (minigraft/PRP and minigraft only) as regards size and site of treated patches	89
Table (8):	Description of the response rate as regards the ideal repigmentation in two treatment modalities (minigraft/PRP and minigraft only) and in the overall study	91
Table (9):	Comparison between the two treatments modalities (minigraft/PRP and minigraft only) as regards clinical efficacy after 8 and 20 weeks of treatment	93
Table (10):	Comparison between the bFGF skin level before and after each treatment modalities (minigraft\PRP and minigraft only), and the percent of change in bFGF between the two treatment modalities (minigraft\PRP and minigraft only).....	97
Table (11):	Comparison between the treatment modalities (minigraft\PRP and minigraft only) as regards minigraft complications.....	104

List of Tables Cont...

Table No.	Title	Page No.
Table (12):	Relation between the degree of repigmentation in minigraft/PRP treated sites and cases' personal and clinical characteristics.....	108
Table (13):	Relation between the degree of repigmentation in graft only treated sites and cases' personal and clinical characteristics	109
Table (14):	Relation between the degree of repigmentation in graft/PRP treated sites and bFGF level.....	110
Table (15):	Relation between the degree of repigmentation in graft only treated sites and bFGF level.....	112
Table (16):	Correlation between bFGF and percent of repigmentation at 16 wk after treatment in graft+prp treated patches	113
Table (17):	Correlation between bFGF and percent of repigmentation at 16 wk after treatment in graft only treated patches	114

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Typical skin lesion of the hands with asymptomatic whitish macule, regular borders and sharp margins	15
Figure (2):	Trichrome vitiligo	16
Figure (3):	Quadrichrome vitiligo	16
Figure (4):	Pentachrome vitiligo	17
Figure (5):	Common vitiligo	21
Figure (6):	Segmental vitiligo	22
Figure (7):	The relationship between the clinical type of vitiligo and the remaining melanocytes from the follicular and epidermal reservoir	31
Figure (8):	Rule of nines in burn assessment	32
Figure (9):	Targeted UVB phototherapy (Bioskin)	42
Figure (10):	Punch grafting	48
Figure (11):	Punch grafting. Six-month development of repigmentation halos, with more than 90% repigmentation	48
Figure (12):	Cobblestoning after minigrafting with 2.5mm punches	49
Figure (13):	Minigrafting with smaller 1.5mm punches leading to less cobblestoning effect	50
Figure (14):	Platelts release growth factors	56
Figure (15):	Treatment options for vitiligo	66
Figure (16):	The Vitiligo Extent Score for a Target Area (VESTA)	71
Figure (17):	Donor sites from upper inner thigh	73
Figure (18):	Centrifugation device	75
Figure (19):	A 2 mm punch biopsy tool	76

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (20):	A 15 years old female with a localized vitiliginous area over the right wrist	77
Figure (21):	NB-UVB phototherapy device.	78
Figure (22):	Wuhan Fine Biological Tecnology® Human bEGF ELISA Kit.	79
Figure (23):	Fibroblast growth factor standard Curve.....	83
Figure (24):	Skin type among studied cases.....	87
Figure (25):	Comparison between the two treatments (minigraft/PRP and minigraft only) as regards size of the treated patches.....	90
Figure (26):	Comparison between the two treatments modalities (minigraft/PRP and minigraft only) as regards VESTA score at weeks 8 and 20.	94
Figure (27):	Comparison between the two treatments modalities (minigraft/PRP and minigraft only) as regards quality of color at week 8 of treatment.	94
Figure (28):	Comparison between the two treatments modalities (minigraft/PRP and minigraft only) as regards quality of color at week 20 of treatment.....	95
Figure (29):	A 13 years old female patient with stable non segmental vitiligo for 2 years duration.	98
Figure (30):	A 18 years old male patient with stable non segmental vitiligo for 2 years duration.	99
Figure (31):	A 19 years old male patient with stable non segmental vitiligo for 3 years duration.	100

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (32):	A 18 years old female patient with stable non segmental vitiligo for 4 years duration.	101
Figure (33):	A 10 years old male patient with stable non segmental vitiligo for 5 years duration.	102
Figure (34):	Cobblestone appearance in recipient sites.	104
Figure (35):	Color mismatching (hyperpigmentation) in recipient sites.	105
Figure (36):	Local infection in recipient sites.	105
Figure (37):	Static graft in recipient sites.	106
Figure (38):	Relation between the expression of bFGF at week 20 and achievement of ideal repigmentation in response to minigraft/PRP.	111
Figure (39):	Relation between expression of bFGF at week 20 and achievement of ideal repigmentation in response to minigraft only.	112

List of Abbreviations

Abb.	Full term
6-BH4.....	6R-L-erythro-tetrahydrobiopterin
APS	Autoimmune polyglandular syndrome
bFGF	Basic fibroblast growth factor
CDK4	Cyclic dependent kinase 4
CES	Cultured epithelial suspension
CIE.....	Commission international de l'éclairage
CMS	Cultured melanocyte suspension
DS	Double spin
EGF.....	Epidermal growth factor
FAK.....	Antifocal adhesion kinase
FGF.....	Fibroblast growth factor
FGFR	Fibroblast growth factor receptor
FOXP3	Forkhead box P3 master regulator of the Treg cell
G1 phase	Gap 1 phase
GF	Growth factor
GMC-SF	Granulocyte Monocyte Colony Stimulating Factor
gp100	Glycoprotein 100
H ₂ O ₂	Hydrogen peroxide
HGF.....	Hepatocyte Growth Factor
HLA-A2.....	Human leukocyte antigen-A2
HS	Highly significant
ICAM-1	Intracellular adhesion molecule-1
IFN- γ	Interferon gamma
IGF.....	Insulin like growth factor
IL.....	Interleukin
IQR.....	Interquartile range
JNK.....	C. Jun NH2-terminal kinase protein

List of Abbreviations Cont...

Abb.	Full term
KGF	Keratinocyte growth factor
MART-1	Melanoma antigen recognized by T cells 1
MBEH.....	Monobenzyl Ether of hydroquinone
MC1R.....	Melanocortin 1 receptor
MED.....	Minimal erythematous dose
MG	Minigraft
NCES	Non-cultured epidermal suspension
NO.....	Nitric oxide
NS	Non significant
NSV.....	Non-segmental vitiligo
O.D.....	Optic density
ONOO-.....	Peroxynitrite anion
PASI.....	Psoriasis area severity index
PBS	Phosphate buffered saline
PDGF	Platelet-derived growth factor
PI3K/AKT	Phosphatidylinositol-3-kinase/serine/threonine protein kinase
PPP	Platelet poor plasma
pRb.....	Retinoblastoma protein
PRI.....	Potential regimentation index
PRP	Platelet rich plasma
PSG.....	Partial thickness skin graft
PUVA.....	Psoralen plus ultraviolet A
r.p.m.....	Revaluation per minute
Rac1	Guanosine triphosphatases (GTPases) protein
RNS.....	Reactive nitrogen species
ROS.....	Reactive oxygen species
RPE.....	Retinal pigment epithelium

List of Abbreviations Cont...

Abb.	Full term
r_s	Spearman's correlation coefficient
S	Significant
S. phase	DNA synthesis phase
SBEG	Suction blister epidermal graft
SCF	Stem cell factor
SD	Standard deviation
SS.....	Single spin
STSG.....	Split thickness skin graft
SV.....	Segmental vitiligo
TGF- β	Transforming growth factor beta
TNF- α	Tumor necrosis factor- α
TPA.....	Tetradecanoylphorbol acetate
Tregs	Regulatory T
TRP-1	Tyrosinase-related protein one
TRP-2	Tyrosinase-related protein two
U-test	Mann-whitney test
UV	Ultraviolet
UVA	Ultraviolet-A
UVB	Ultraviolet B
VASI	Vitiligo area scoring index
VEGF	Vascular endothelial growth factor
VESTA.....	Vitiligo extent score for a target area
VETF	Vitiligo European taskforce assessment
VETI	Vitiligo extent-tensity index
VIDA.....	Vitiligo disease activity score

1. INTRODUCTION

Vitiligo is an acquired pigmentary disorder resulting from loss of melanocytes which causes depigmentation of the skin. Clinically, it is characterized by the progressive loss of melanocytes causing the appearance of well-circumscribed milky white cutaneous macules and patches (*Felsten et al., 2011*). The worldwide prevalence is estimated to be 0.5-2% of the general population (*Krüger and Schallreuter, 2012*). Vitiligo is generally classified in three forms: non-segmental vitiligo (NSV), a group which includes the acrofacial, mucosal, generalized, universal and mixed forms; segmental vitiligo (SV), which can be unisegmental, bisegmental, or multisegmental; and the unclassified or undetermined form (*Faria et al., 2014*).

The exact etiology of vitiligo has been proposed of many competing theories. The autoimmune theory is the most accepted one, being sustained by several epidemiological, clinical, and experimental findings (*Patel et al., 2017*). It is suggested that melanocyte destruction in susceptible individuals is triggered through an autoimmune response. Several exogenous and endogenous stimuli have been linked to the onset of the disease. The exogenous factors include ultraviolet irradiations, trauma (Koebner phenomenon), stress, major infections, malignancies, neural abnormalities, calcium imbalance, certain drugs, hormones, and exposure to cytotoxic

compounds (**Rodrigues et al., 2017**). All are thought to induce oxidative stress in melanocytes, as indicated by the high levels of reactive oxygen species (ROS), mainly hydrogen peroxide, found in lesional skin (**Sravani et al., 2009; Picardo and Bastonini, 2015**).

Treatment for vitiligo is difficult and often challenging. Treatment options include corticosteroids, calcineurin inhibitors, vitamin D analogues, antioxidants, phototherapy using ultraviolet B (UVB), psoralen plus ultraviolet A (PUVA), narrow-band UVB, excimer laser (**Felsten et al., 2011; Patel et al., 2012**).

Surgical alternatives represent good options for patients not responding to the above-mentioned therapies; however, surgery is limited to segmental or localized vitiligo. The main purpose of the surgical treatment is to restore melanocytes on the target sites. The repigmentation process should begin when the transplanted cells survive the procedure since melanin is transferred by melanocytes to keratinocytes pass through the dendritic process, giving the skin color and natural appearance. There are 5 basic methods for repigmentation surgery which are thin dermoepidermal grafts, suction epidermal grafting, punch minigraft, noncultured epidermal suspension and cultured melanocyte suspension (**Van Geel et al., 2001**).

Among these surgical approaches, punch minigrafting represents a simple and effective procedure, which involves performing multiple perforations in the recipient

depigmented site using biopsy punches and transplanting similar size punches taken from a normally pigmented donor site. Punch grafting followed by NB-UVB was found to be effective in inducing repigmentation in vitiligo patients (*Lahiri et al., 2006*).

Platelet-rich plasma (PRP) represents a bio technology that is part of the growing interest in tissue engineering and cellular therapy. PRP is an autologous preparation of platelets in concentrated plasma. Although the optimal PRP platelet concentration is unclear, the current method by which PRP is prepared is reported to involve 300-700% enrichment, with high platelet concentrations (*Sclafani, 2009*). PRP has emerged as an attractive treatment modality for many dermatological conditions like treatment acne scars, striae distensae, wound healing, hair re-growth (*Casabona et al., 2010*). The beneficial effects of PRP are thought to be attributed to the released growth factors from the activated platelets (*Hara and Basu, 2014*). Various growth factors have been described to be released from the activated platelets including platelet-derived growth factor, transforming growth factor, vascular endothelial growth factor, basic fibroblast growth factor, insulin like growth factor, epidermal growth factor and connective tissue growth factor (*Marx, 2004*). These factors are known to regulate many processes including cell migration, attachment, proliferation, differentiation, and promoting extra cellular matrix accumulation by binding to specific cell-surface receptors (*Wrotniak et al., 2007*).